Tevogen Bio Social Engagement Event
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
June 07, 2024 15:32 ET | Tevogen Bio Inc
Tevogen social event aimed to understand patients' needs and discuss how its model could reduce healthcare costs and improve patient outcomes.
Tevogen Logo Notified.png
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
June 06, 2024 18:14 ET | Tevogen Bio Inc
Tevogen social event aimed to understand patients' needs and discuss how its model could reduce healthcare costs and improve patient outcomes.
William Keane, Vice President of Strategic Initiatives, Tevogen Bio
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
May 16, 2024 14:00 ET | Tevogen Bio Inc
Former police chief & FBI National Academy graduate, William Keane, to work with functional leads, ensure policies, procure Tevogen’s lab space.
Tevogen Logo Notified.png
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
May 10, 2024 17:40 ET | Tevogen Bio Inc
$50 million in financing advances operational objectives and bolsters a financial path to positive cashflow with minimal dilution.
New Logo.png
Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)
May 02, 2024 08:00 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, May 02, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office has...
Tevogen Logo Notified.png
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
May 01, 2024 08:05 ET | Tevogen Bio Inc
For full year 2023, the operating expenses for Tevogen Bio Inc were $8.8 million.
New Logo.png
Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines
March 12, 2024 08:00 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 12, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office...
22157.jpg
Infectious Disease Diagnostics Market Analysis Reveals Surge in DTC Testing Approaches amid COVID-19
February 23, 2024 06:32 ET | Research and Markets
Dublin, Feb. 23, 2024 (GLOBE NEWSWIRE) -- The "OTC/DTC Infectious Disease Diagnostics Strategies and Trends, COVID-19 Adjusted Forecasts: by Application, by Channel, by Country. With Market...
22157.jpg
In Vitro Diagnostics Market Forecast Reveals Growth Opportunities and Industry Insights for 2024
February 12, 2024 04:36 ET | Research and Markets
Dublin, Feb. 12, 2024 (GLOBE NEWSWIRE) -- The "In Vitro Diagnostics Business Outlook 2024" report has been added to ResearchAndMarkets.com's offering. The latest edition of the In Vitro...
22157.jpg
OTC/DTC Infectious Disease Diagnostics Research Report 2024: Strategies and Trends for OTC and DTC - Market Analysis, Executive Guides, and Market Opportunity Analysis 2023-2027
February 05, 2024 04:12 ET | Research and Markets
Dublin, Feb. 05, 2024 (GLOBE NEWSWIRE) -- The "OTC/DTC Infectious Disease Diagnostics: Strategies and Trends for Over the Counter and Direct To Consumer - Forecasts by Application by Channel and by...